Adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Any adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Souvenaid showed no clear difference in any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of people with adverse events · people with dementia and mild to moderate pain
1 finding from 1 review
Intervention not reported
Number of people with serious adverse events · people with dementia and mild to moderate pain
1 finding from 1 review
Adverse Events ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review